Company performance
Add to research
Current Price
as of May 12, 2025$300.76
P/E Ratio
N/A
Market Cap
$6.68B
Description
Add to research
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Metrics
Add to research
Overview
- HQWest Conshohocken, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerMDGL
- Price$300.76+2.08%
Trading Information
- Market cap$6.68B
- Float90.29%
- Average Daily Volume (1m)375,030
- Average Daily Volume (3m)376,089
- EPS-$18.04
Company
- Revenue$317.38M
- Rev growth (1yr)N/A
- Net income-$73.24M
- Gross margin96.44%
- EBITDA margin-57.51%
- EBITDA-$78.93M
- EV$6.59B
- EV/Revenue20.76
- P/EN/A
- P/S20.93
- P/B9.39
- Debt/Equity16.85
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account